These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37507497)

  • 1. Adjuvant nivolumab shows promise in MCC.
    Killock D
    Nat Rev Clin Oncol; 2023 Nov; 20(11):734. PubMed ID: 37507497
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of a patient with HIV and metastatic melanoma with consequitive ipilimumab and nivolumab.
    Tomsitz D; Hein R; Biedermann T; Kohlmeyer J
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e26-e28. PubMed ID: 28662283
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study.
    Yokota K; Uchi H; Uhara H; Yoshikawa S; Takenouchi T; Inozume T; Ozawa K; Ihn H; Fujisawa Y; Qureshi A; de Pril V; Otsuka Y; Weber J; Yamazaki N
    J Dermatol; 2019 Dec; 46(12):1197-1201. PubMed ID: 31638282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world efficacy of nivolumab plus ipilimumab combination therapy versus nivolumab monotherapy for Stage IV melanoma patients in Asia.
    Maeda T; Hiura A; Uehara J; Toyoshima R; Nakagawa T; Yoshino K
    Eur J Dermatol; 2021 Oct; 31(5):662-664. PubMed ID: 34642136
    [No Abstract]   [Full Text] [Related]  

  • 5. Using immune checkpoint inhibitors without exacerbation in a melanoma patient with pemphigus foliaceus.
    Maeda T; Yanagi T; Imafuku K; Kitamura S; Hata H; Izumi K; Ujiie H; Iwata H; Shimizu H
    Int J Dermatol; 2017 Dec; 56(12):1477-1479. PubMed ID: 28762466
    [No Abstract]   [Full Text] [Related]  

  • 6. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
    Oya K; Nakamura Y; Fujisawa Y; Endo R; Tanaka R; Ishitsuka Y; Maruyama H; Watanabe R; Okiyama N; Fujimoto M
    Eur J Dermatol; 2018 Feb; 28(1):129-130. PubMed ID: 29400284
    [No Abstract]   [Full Text] [Related]  

  • 7. Are checkpoint inhibitors a valuable option for metastatic or unresectable vulvar and vaginal melanomas?
    Quéreux G; Wylomanski S; Bouquin R; Saint-Jean M; Peuvrel L; Knol AC; Hanf M; Dréno B
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e39-e40. PubMed ID: 28750150
    [No Abstract]   [Full Text] [Related]  

  • 8. No recurrence of nivolumab-induced idiopathic thrombocytopenic purpura in a metastatic melanoma patient switched to ipilimumab.
    Takimoto R; Otsuka A; Kaku Y; Honda T; Kabashima K
    Eur J Dermatol; 2018 Feb; 28(1):84-85. PubMed ID: 29400292
    [No Abstract]   [Full Text] [Related]  

  • 9. Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma.
    Weber JS; Ascierto PA; Middleton MR; Hennicken D; Zoffoli R; Pieters A; Amadi A; Kupas K; Kotapati S; Moshyk A; Schadendorf D
    Eur J Cancer; 2021 Nov; 158():225-233. PubMed ID: 34663559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant ipilimumab-nivolumab superior to adjuvant nivolumab.
    Sidaway P
    Nat Rev Clin Oncol; 2024 Aug; 21(8):566. PubMed ID: 38877176
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
    Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
    Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of PD-L1, PD-1, and CTLA-4 Expression in the Clinical Practice as Predictors of Response to Nivolumab and Ipilimumab in Monotherapy in Patients With Advanced Stage Melanoma.
    Santos-Briz A; Cañueto J; Carmen SD; Barrios B; Yuste M; Bellido L; Ludeña MD; Román C
    Am J Dermatopathol; 2021 Jun; 43(6):423-428. PubMed ID: 33395045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England.
    Meng Y; Hertel N; Ellis J; Morais E; Johnson H; Philips Z; Roskell N; Walker A; Lee D
    Eur J Health Econ; 2018 Nov; 19(8):1163-1172. PubMed ID: 29524005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab for adjuvant treatment of desmoplastic malignant melanoma: A case report.
    Shibata T; Iwashita N; Takama H; Yanagishita T; Takeo T; Oshima Y; Watanabe D; Tsuzuki T
    J Dermatol; 2020 Jan; 47(1):e6-e7. PubMed ID: 31701575
    [No Abstract]   [Full Text] [Related]  

  • 15. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
    Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
    Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case of metastatic uveal melanoma in which an antitumor effect appeared after ipilimumab discontinuation due to autoimmune hypophysitis.
    Ohnuma T; Matsuzawa T; Kinoshita M; Sano S; Kawamura T; Shimada S; Inozume T
    J Dermatol; 2017 Nov; 44(11):1325-1326. PubMed ID: 27864834
    [No Abstract]   [Full Text] [Related]  

  • 17. Adjuvant Nivolumab or Ipilimumab + Nivolumab for Melanoma Determined by Pathological Response to a Single Dose of Neoadjuvant Nivolumab.
    Khan TM; Teke ME; Karakousis GC; Miura JT; Brody RM; Hernandez JM; Mitchell TC
    Ann Surg Oncol; 2022 May; 29(5):2771-2772. PubMed ID: 35061122
    [No Abstract]   [Full Text] [Related]  

  • 18. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients.
    Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Uchi H; Fujimura T; Matsushita S; Hata H; Okuhira H; Tanaka R; Nagai K; Ishida Y; Nakamura Y; Furudate S; Yamamura K; Imafuku K; Yamamoto Y
    J Dermatol Sci; 2018 Jan; 89(1):60-66. PubMed ID: 29079332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review.
    Moujaess E; Haddad FG; Eid R; Kourie HR
    Immunotherapy; 2019 Nov; 11(16):1409-1422. PubMed ID: 31621445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant Therapy of Melanoma.
    Tarhini AA
    Hematol Oncol Clin North Am; 2021 Feb; 35(1):73-84. PubMed ID: 33759774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.